Table 1 Baseline characteristics
All patients (n = 602) | Bleeding Events | p-value | ||
|---|---|---|---|---|
Bleeding (n = 95) | Non-bleeding (n = 507) | |||
Male sex, n (%) | 381 (63.3) | 56 (59.0) | 325 (64.1) | 0.339 |
Age, years (mean ± SD) | 68.2 ± 12.0 | 70.4 ± 9.7 | 67.8 ± 12.4 | 0.025 |
Age ≥ 65 years, n (%) | 393 (65.3) | 74 (77.9) | 319 (62.9) | 0.005 |
Weight, kg (mean ± SD) | 62.9 ± 12.9 | 61.9 ± 11.5 | 63.0 ± 13.2 | 0.441 |
BMI, kg/m2 (mean ± SD) | 24.1 ± 4.0 | 23.8 ± 3.6 | 24.2 ± 4.1 | 0.340 |
SBP, mmHg (mean ± SD) | 136.5 ± 27.2 | 135.7 ± 31.2 | 136.6 ± 26.4 | 0.786 |
SBP ≥ 160 mmHg, n (%) | 130 (21.6) | 25 (26.3) | 105 (20.7) | 0.223 |
Heart rate, bpm (mean ± SD) | 83.8 ± 18.6 | 84.6 ± 18.3 | 83.6 ± 19.1 | 0.638 |
CrCl, mL/min (mean ± SD) | 54.6 ± 26.0 | 52.8 ± 23.5 | 55.0 ± 26.4 | 0.453 |
CrCl < 30 mL/min, n (%) | 101 (16.8) | 16 (16.8) | 85 (16.8) | 0.985 |
Hemoglobin, g/dL (mean ± SD) | 12.6 ± 4.3 | 12.2 ± 2.4 | 12.8 ± 4.6 | 0.200 |
Platelet, × 103 cells/µL (mean ± SD) | 253.7 ± 89.0 | 245.5 ± 95.4 | 255.2 ± 87.8 | 0.328 |
WBC, × 103 cells/ µL (mean ± SD) | 10.3 ± 4.2 | 10.2 ± 4.0 | 10.3 ± 4.3 | 0.882 |
Medical history, n (%) | ||||
Hypertension | 395 (65.6) | 72 (75.8) | 323 (63.7) | 0.023 |
Diabetes mellitus | 286 (47.5) | 47 (49.5) | 239 (47.1) | 0.676 |
Coronary artery disease | 221 (36.7) | 41 (43.2) | 180 (35.5) | 0.155 |
Cerebrovascular disease | 91 (15.1) | 20 (21.1) | 71 (14.0) | 0.078 |
History of bleeding in 1 year | 14 (2.3) | 6 (6.3) | 8 (1.6) | 0.014 |
History of oral anticoagulant used | 17 (2.8) | 8 (8.4) | 9 (1.8) | 0.002 |
History of NSAIDs used | 19 (3.2) | 7 (7.4) | 12 (2.4) | 0.019 |
Signs and symptoms at presentation, n (%) | ||||
Anemia | 299 (49.7) | 50 (52.6) | 249 (49.1) | 0.529 |
Signs of heart failure | 244 (40.5) | 37 (39.0) | 207 (40.8) | 0.732 |
Diagnosis of ACS, n (%) | ||||
Unstable angina | 20 (3.3) | 4 (4.2) | 16 (3.2) | 0.539 |
NSTEMI | 422 (70.1) | 69 (72.6) | 353 (69.6) | 0.557 |
STEMI | 160 (26.6) | 22 (23.2) | 138 (27.2) | 0.411 |
In-hospital management, n (%) | ||||
Conservative strategy | 91 (15.1) | 21 (22.1) | 70 (13.8) | 0.038 |
CAG | 475 (78.9) | 68 (71.6) | 407 (80.3) | 0.057 |
Femoral access | 439 (92.4) | 65 (95.6) | 374 (91.9) | 0.286 |
Radial access | 36 (7.6) | 3 (4.4) | 33 (8.1) | Ref |
PCI | 297 (49.3) | 47 (49.5) | 250 (49.3) | 0.977 |
CABG | 59 (9.8) | 8 (8.4) | 51 (10.1) | 0.622 |
P2Y12 receptor inhibitor, n (%) | ||||
Clopidogrel | 544 (90.4) | 81 (85.3) | 463 (91.3) | 0.066 |
Prasugrel | 2 (0.3) | 0 (0) | 2 (0.4) | 1.000 |
Ticagrelor | 40 (6.6) | 9 (9.5) | 31 (6.1) | 0.228 |